The role of histone deacetylase inhibitors in metastatic breast cancer.

The role of histone deacetylase inhibitors in metastatic breast cancer.

Breast. 2018 Dec 06;43:130-134

Authors: Zucchetti B, Shimada AK, Katz A, Curigliano G

Abstract
Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice.

PMID: 30553187 [PubMed - as supplied by publisher]

from A via a.sfakia on Inoreader https://ift.tt/2LihJQq